Background: Current American Joint Committee on Cancer retroperitoneal sarcoma (RPS) staging is not representative of patients with RPS specifically and has limited discriminative power. Our objective was to develop a RPS disease-specific nomogram capable of stratifying patients based on probability of overall survival (OS) after resection.
introduction
Retroperitoneal sarcoma (RPS) is a group of rare mesenchymal tumors comprising 10% of all soft tissue sarcomas (STS), with an estimated annual incidence of 1000 new cases in the United States [1] . Due to specific disease characteristics, improvement in long-term outcomes has remained challenging over the last few decades, with a stagnant and modest 5-year overall survival (OS) rate of 50% and a 5-year local recurrence rate close to 70% [2] . Surgery remains the only curative treatment; the role of chemotherapy or radiation therapy is controversial and still needs to be defined [3] . Accurate risk stratification is critical in guiding treatment strategies and for effective patient counseling. Similarly, identification of highrisk groups allows focused research efforts that may help in establishing the role of adjuvant and novel therapies in this group of patients.
Multiple prognostic factors in RPS have been identified [4] [5] [6] [7] ; however, few studies have tried to integrate these into a prognosticating tool [8] . Further, current American Joint Committee on Cancer (AJCC) STS staging [9] is derived from data examining prognostic factors in patients with extremity STS [10] ; due to essential differences in disease characteristics, its applicability in staging RPS has been questioned by multiple authors [2, 8, 11, 12] . Likewise, in a recently published nomogram used to predict death after surgical treatment in patients with STS, the majority of study patients had extremity or trunk STS with RPS comprising <15% [13] . This nomogram has been validated using several different institutional datasets and is demonstrably accurate in generally predicting survival for patients with STS; however, only 13% of the patients in the validating datasets had STS originating in the retroperitoneum [14] . This latter factor limits the applicability of this tool for this patient population, in which additional key prognostic factors specific to the retroperitoneal location have been identified; however, these have not been included in the STS nomogram discussed above.
Based on the above considerations and with the goal of creating a dynamic prognostic tool able to integrate relevant factors specific to RPS, the main objective of this study was to develop a robust nomogram to predict survival after surgical treatment of RPS patients.
patients and methods

patient selection
This study was approved by the institutional review board of the University of Texas M.D. Anderson Cancer Center. We used the M.D. Anderson prospective STS database (n > 6700 STS patients) to identify 1118 RPS patients (exclusive of desmoid and gastrointestinal stromal tumors) evaluated at our center from 1996 to 2006. Of these, 510 patients received treatment at M.D. Anderson, and after excluding those with metastatic disease (n = 116) and those deemed unresectable (n = 51), a total of 343 patients with nonmetastatic, resectable RPS were selected and constitute the cohort of this analysis. The patients' medical records were reviewed and demographic, clinicopathologic, treatment and outcomes variables were retrieved. All patients (n = 343) were prospectively evaluated by a sarcoma team at M.D. Anderson and surgical resection was offered. Adjuvant therapies including chemotherapy (primarily doxorubicin based) and radiation therapy were selectively used as deemed appropriate by the treating physicians. Postsurgical surveillance consisted of computed tomography imaging carried out every 3-4 months for the first 5 years after resection and annually thereafter.
patient's characteristics and variable definition
All 343 patients included in this analysis had nonmetastatic resectable RPS. Resectability was typically determined in the preoperative setting and variables including surgical candidacy, extent of operation and technical feasibility were used to identify those patients in whom curative resection with gross complete excision could be safely achieved. Primary RPS were defined as newly diagnosed tumors without any previous surgical treatment. Recurrent tumors were defined as those presenting at least 3 months after a curative resection. When more than one noncontiguous tumor was identified, the disease was classified as multifocal. Size of the tumor (or largest tumor when multifocal disease was present) was initially recorded as a continuous variable. After univariate and multivariate analysis, this variable was dichotomized based on its effect on survival. All the above variables were determined using a combination of clinical information as well as pre-and postoperative imaging and intraoperative findings, as applicable.
Histology was classified using the World Health Organization classification scheme for STS histological subtypes [15] . We then categorized all tumors into three main histological groups: welldifferentiated liposarcoma (WD LPS), dedifferentiated/pleomorphic liposarcoma (DD LPS) and 'other' histology. This histological categorization was used based on our work [16] [17] [18] and work from others [19, 20] , showing that liposarcomas (LPS) constitute the most common histological subtype when evaluating RPS and that clinicopathologic, treatment and outcome characteristics vary markedly between these RPS histological subtypes. Recent work from our institution has shown that this three-group classification is more discriminative than current AJCC STS staging when applied to RPS [21] . Due to the lower discriminative power of grade as compared with histological subtype, the former was recorded for descriptive purposes only using the three-tiered French grading system [22] .
A complete resection was defined as achieving gross (macroscopic) excision of the whole tumors as determined at the time of operation by the operating surgeon. Other treatment strategies, including chemotherapy and radiation therapy, were recorded and included in the analysis.
statistical analysis
OS was the primary outcome of this analysis and was calculated as the interval from the date of diagnosis of the current disease (primary or recurrent) until the date of death. Univariate analysis using Kaplan-Meier curves and the log-rank test was carried out for the following variables: age, gender, type of presentation, location, multifocality, size, histology, completeness of resection, chemotherapy and radiation therapy. Variables with a P value of <0.1 were included in the multivariate analysis.
To develop the nomogram, a multivariate Cox proportional hazards model was fit. Variables with a P <0.05 were considered independent predictors of survival and used to model the nomogram. Additionally, clinically relevant variables were also included in the nomogram; specifically, type of presentation, although not statistically significant after multivariate analysis, was included in the nomogram due to its prognostic value as reported in previous series [2, 4, 6] . A nomogram using these variables was created to predict median, 3-and 5-year OS.
The performance of the nomogram was evaluated by quantifying discrimination and calibration [23] . To reduce the overfit bias, the nomogram was subjected to 200 bootstrap resamples for internal validation. The bootstrap-estimated concordance index was calculated. The cordance index is the probability that given two randomly selected patients, the patient with the worse outcome will have a worse outcome prediction. The concordance index ranges from 0 to 1, with 1 indicating perfect concordance and 0 indicating perfect discordance. Calibration, which is the agreement between observed outcome frequencies and predicted probabilities, was studied with a visual inspection of the plot comparing the predicted probability of OS with the observed outcome.
All statistical analyses were two sided and carried out using S-Plus software (Insightful Corporate, Seattle, WA). results patient characteristics Table 1 depicts descriptive features of the patient population including demographic and clinical characteristics, histological features and treatment variables. The median age was 58 years (range 18-88 years) and recurrent disease was present in almost one-third of the cohort (30%). The median size of tumors was 13 cm (range 2-100 cm) with almost half (46%) measuring >15 cm; <10% were tumors <5 cm. The most common histology was LPS representing 43% of all tumors, followed by leiomyosarcoma (18%) and unclassified sarcoma (17%). The majority of tumors (80%) were characterized as having intermediate-or high-grade histology. Complete resection was achieved in 90% of the patients and the operation involved resection of associated organs in 69% of the cases.
survival analysis
The median follow-up for this cohort was 50 months [95% confidence interval (CI) 45-57 months]. The OS for the whole cohort is illustrated in Figure 1 ; median OS was 59 months (95% CI 48-75 months), with 3-and 5-year OS of 64% (95% CI 59% to 70%) and 50% (95% CI 44% to 57%), respectively. Results from the multivariate Cox proportional hazards model identified the following independent predictors of worse survival ( Table 2) : age ‡65, size ‡15 cm, multifocal disease, incomplete resection and non-WD LPS histology. Regarding histology, three different risk groups were identified: WD LPS, DD LPS and other histology. Recurrent disease was associated with worse survival in the univariate analysis; however, this association was not significant in the multivariate analysis.
nomogram model
The Cox model was used as the basis for the nomogram (Table 2 ). Figure 2 depicts the final nomogram and portrays the association between each variable and survival based on the scoring system derived from this analysis. The concordance index (discrimination) after internal validation with 200 bootstrapping resamples was 0.73 (95% CI 0.71-0.75). Similarly, Figure 3 illustrates the calibration of the nomogram before and after internal validation with bootstrapping samples. Calibration was excellent with observed outcomes always within 95% CI of the predicted survival probability.
discussion Risk stratification and evidence-based treatment strategies in patients with RPS are limited by patient heterogeneity and by the rarity of this disease [1] . Prognostic factors for survival have been identified but are typically derived from small retrospective series of heterogeneous patients [5, 6, 24] , often including those with unresectable or metastatic disease [4, 8] . Therefore, integrating predictors of outcome to achieve an accurate prognostic assessment is a challenging task in RPS. Current staging for RPS is carried out using the AJCC 6th edition staging for STS; a significant compromise in that the AJCC system was derived from analysis of patients with extremity and trunk STS and anatomic loci of STS that have markedly different biological behavior compared with STS of the retroperitoneum. Moreover, current staging tools are evolving to incorporate additional predictors of outcome beyond those traditionally included in tumor-node-metastasisdenominated systems. Nomograms have proven useful in this regard by facilitating inclusion of important new factors while integrating their combined effect on survival. Such is the case for STS [13] , gastric cancer [25] , pancreatic cancer [26] and hepatocellular carcinoma [27] , as exemplary of diseases for 
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which nomograms have recently been published. Despite these potential advantages, before this effort no staging nomograms have ever been developed specifically for RPS. Presented here is a RPS-specific postoperative nomogram designed to evaluate individual patient probability of OS after resection. The nomogram uses age, size, type of presentation, multifocality, completeness of resection and histological subtype to estimate survival probability. Internal validation revealed good performance with a concordance index of 0.73 and accurate calibration such that all observed deaths were within the 95% CI of all predictions. This nomogram improves risk stratification of RPS patients by providing a more accurate, individualized and dynamic assessment of the probability of survival for each patient. This tool can help guide clinicians called on to discuss survival probabilities when counseling patients, to generate surveillance recommendations and to identify high-risk patients who may benefit from either established adjuvant therapies or by participation in RPS clinical trials.
This nomogram utilizes a score system for each variable from which a predicted probability of survival is calculated by adding the points derived from each predictor. The advantage of this nomogram versus other tools currently used to stratify RPS patients is that it is derived from a large homogeneous patient cohort characterized as having nonmetastatic, resectable RPS disease. Also, the comprehensive nature of our STS database enabled statistically robust inclusion of known prognostic factors and other variables not previously examined with rigor in the context of RPS, thereby enabling evaluation of the specific individual impact of each variable on survival while also considering their interaction as well. Well-established prognostic factors such as age [5, 24, 28] persisted as an important variable. Size, a well-recognized prognostic factor in patients with STS [9, 10] proved to be an important predictor of outcome in RPS when higher thresholds of tumor size were employed compared with the traditional 5-cm cut-off used for extremity STS. The improved predictive value of higher thresholds for the variable of size when applied to STS has been recently emphasized in other reports [12, 29] . As visualized in the nomogram, multifocality, a previously understudied but common and important feature in RPS [5, 7, 30] , has an even Median Survival Time (Yrs) original article Annals of Oncology greater impact on survival; when considered with histology, the effect of other previously reported predictors are markedly modified (see discussion of recurrence below). This nomogram specifically predicts the probability of survival after surgical treatment of RPS. By designing a postoperative nomogram, we were able to homogenize the patient population studied to include those treated with curative intent (resectable disease) and in whom local disease would drive prognosis (nonmetastatic). It is well documented that the natural course of RPS differs from that of STS originating elsewhere, reflecting the major local anatomic constraints on STS resectability that contribute to lower rates of microscopic-negative resections which in turn leads to higher local failure and lower survival rates. This highlights the wellrecognized impact of completeness of resection on survival [2, 4, 5] . Ignoring this critical factor when considering prognosis for RPS patients would significantly compromise the accuracy of this tool as demonstrated by the strong effect of this variable on survival observed as per this nomogram.
The inclusion of histology and type of presentation both warrant special comment. First, due to their close correlation, inclusion of histology limited the role of grade as a potential variable in the nomogram. Although grade has proven to be a good predictor of STS outcome in general [9, 10] , its predictive value has been limited to stratification into only two risk groups (low-grade tumors versus intermediate-and highgrade tumors) [12, 13] and its predictive utility is more appropriate for extremity STS patients in whom distant metastasis is the cardinal event-driving survival. This is in contrast to the situation in RPS. Given the less variable histological subtype distribution in RPS [2, 4, 6] as well as the radically different outcomes observed as a function of histological subtype [2, 16, 18, 19] , histology was used as the main tumor feature used to predict outcome in RPS. Recently, we have shown that a three-tiered prognostic system based on histological subtype is a more robust predictive variable than one based on grade (stages I or II/III in the AJCC staging system) [21] . Histological subtype is a more comprehensive tumor biology descriptor in RPS and therefore is a better tumor-based prognosticator than grade in this disease site. A comparable strategy has been used in other disease-specific nomograms and prognostic algorithms leading to better accuracy of prediction [18, 19] ; the strong association between histology and survival is demonstrated by the wide score range accorded this variable in the nomogram.
Secondly, the role of primary versus recurrent presentation status as a prognostic factor might be questioned after evaluating our analysis. Recurrent tumors have traditionally been perceived as having worse outcomes in RPS patients, and multiple studies have supported this perception [2, 4] . In univariate analysis, the negative survival impact of recurrent tumors was suggested; however, this relationship did not remain significant on multivariate analysis. This can be explained by the analytic addition of other variables that are closely related to recurrent tumors, facilitating identification of factors (i.e. multifocality and histology) that confound this previously observed association. We and others have demonstrated increased rates of multifocality in patients presenting with recurrent tumors [7, 30] as well as the strong association between recurrent tumors and more aggressive histologies [4, 6] . In our database, recurrent tumors were more likely to present with multifocal disease (P < 0.0001) and less likely to have WD LPS histology (P = 0.001). However (and despite this observation), adding type of presentation to our nomogram did not affect the concordance index and slightly improved the calibration accuracy, while allowing identification of two different patient groups that can be easily categorized at time of initial consultation, a benefit that can be exploited in selecting homogeneous STS subgroups for clinical trials.
The accuracy of this RPS-specific nomogram compares favorably with other prognostic tools. Similar prognostic tools used in clinical practice for other cancer sites have reported concordance index between 0.62 and 0.82; although our results fall well within this adequate standard, the true advantage of a given nomogram is in its putative ability to improve risk stratification compared with other competing systems. No such RPS-specific system exists, and current RPS staging is still conducted using the patently not applicable AJCC system for STS in general. This nomogram has the advantage of more dynamic and robust risk stratification than the limited twotiered risk categorization of the AJCC system when applied to nonmetastatic RPS (stage I versus stages II and III). Moreover, the accurate calibration of this tool highlights the applicability of this tool, with good performance even when applied to RPS patients possessing different features.
This study has several limitations. First are those related to the use of retrospective data for the analysis. We sought to mitigate this potential problem by including a large number of strictly defined variables in our analysis. Secondly, this nomogram uses information which only becomes available after surgical treatment, thereby excluding its use in patients whose disease is not resectable and in patients for whom prognostic-based decisions are needed regarding preoperative treatment, including clinical trial access. This liability is balanced by the ability of this tool to accurately identify a selected group of patients for whom potentially curative treatment has been carried out. While the performance of this nomogram has been verifiably useful in our own RPS patient cohort, further validation with databases incorporating RPS patient experiences at other institutions is needed and would be welcomed.
In conclusion, we offer the first RPS-specific staging nomogram useful to assess postoperative prognosis for patients with nonmetastatic, resectable disease. This nomogram uses common and readily available variables to accurately predict OS for the individual RPS patient. It improves current RPS staging, as demonstrated by adequate nomogram discrimination and calibration and more dynamic and robust risk stratification. This tool can be used when counseling patients, to establish appropriate surveillance strategies, and for selecting patients who may benefit from adjuvant therapies and/or inclusion in clinical trials.
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